Open access
Jul 2026
Real‐world implementation of lecanemab in Alzheimer's disease: A Japanese cohort
Abstract INTRODUCTION Real‐world evidence for lecanemab remains limited, particularly among Asian populations. We evaluated the feasibility, safety, biomarker profiles, and short‐term clinical outcomes of lecanemab in practice in Japan. METHODS We screened 321 patients with early Alzheimer's disease (AD) and confirmed...
S. Shimohama, S. Bun, Ryo Shikimoto et al.
· Alzheimer's & Dementia · 0 citations